Opening subject page...
Loading your content
Understanding how the FDA expedites access to critical medical countermeasures during public health emergencies.
The concept of an Emergency Use Authorization (EUA) arose from the recognition that the traditional FDA drug and device approval process — which can span years of clinical trials and regulatory review — is fundamentally incompatible with the urgent timelines imposed by public health emergencies. When novel biological threats, chemical exposures, or pandemic pathogens emerge, healthcare systems require rapid access to unapproved or investigational medical products that may save lives, even when full safety and efficacy data remain incomplete. The legislative framework for EUAs was designed to bridge this gap by allowing the FDA Commissioner to authorize use of medical countermeasures under specific conditions of declared emergency.
Before EUAs existed, the federal government had limited options for distributing unapproved products during emergencies. The Investigational New Drug (IND) pathway or compassionate use protocols could serve individual patients, but these mechanisms were not designed for mass-scale deployment of countermeasures to millions of people simultaneously. The anthrax attacks of 2001 crystallized this deficiency and catalyzed Congressional action to create a more agile regulatory tool.
This historical trajectory raises a central question for pharmacy practice: How does the EUA framework balance the urgency of population-level need against the individual patient's right to fully vetted, safe, and effective medical products? Understanding the legal basis, procedural requirements, and pharmacist responsibilities surrounding EUAs is essential for any practitioner who may dispense or administer these products.
An Emergency Use Authorization is a regulatory mechanism codified in Section 564 of the FD&C Act (21 U.S.C. §360bbb-3) that permits the FDA to authorize the use of unapproved medical products, or unapproved uses of approved medical products, during a declared emergency. Unlike traditional FDA approval — which requires substantial evidence of safety and effectiveness from adequate and well-controlled clinical trials — an EUA requires a lower evidentiary threshold: that the product may be effective and that the known and potential benefits outweigh the known and potential risks. This distinction is critical for pharmacists to understand, as it defines the informed consent landscape and the scope of conditions under which EUA products may be dispensed.
The process illustrated above is not strictly linear; at any point the FDA may request additional data from the sponsor, convene an advisory committee for independent expert review, or modify conditions on an existing EUA as new safety signals emerge. During the COVID-19 pandemic, for instance, the Vaccines and Related Biological Products Advisory Committee (VRBPAC) held public meetings before the FDA issued EUAs for each COVID-19 vaccine. These meetings, while not legally required for EUAs, served to enhance public confidence and transparency. Pharmacists should understand that the iterative nature of this process means the conditions of authorization — including eligible patient populations, dosing intervals, and storage requirements — can change rapidly, necessitating ongoing vigilance and communication.
The legal foundation for EUAs rests on Section 564 of the FD&C Act, which establishes four types of emergency or threat determinations that can trigger EUA authority. The Secretary of HHS may determine that (1) a domestic emergency exists, or a significant potential exists for a domestic emergency, involving a heightened risk to national security from a CBRN agent; (2) a military emergency or a significant potential for one exists; (3) an emergency exists that affects or has a significant potential to affect national security and involves a CBRN agent or agents; or (4) there is a material threat sufficient to affect national security or the health and security of U.S. citizens abroad. A key update from PAHPRA (2013) added a fourth pathway specifically for material threats, enabling the Secretary of HHS to make a "threat-based" determination that can activate pre-EUA activities even before an actual emergency unfolds.
Once an appropriate declaration or determination is in effect, the FDA Commissioner may issue an EUA only if all four statutory criteria are satisfied. First, the agent referred to in the declaration can cause a serious or life-threatening disease or condition. Second, based on the totality of scientific evidence available — including data from adequate and well-controlled clinical trials if available — it is reasonable to believe the product may be effective in diagnosing, treating, or preventing the disease or condition. Third, the known and potential benefits of the product outweigh the known and potential risks. Fourth, there is no adequate, approved, and available alternative to the product for diagnosing, preventing, or treating the disease or condition.
The FDA is authorized to impose conditions of authorization that are tailored to each specific product and emergency context. These conditions are binding and may be directed at manufacturers, healthcare providers (including pharmacists), or patients. Common conditions include: distribution of FDA-authored Fact Sheets for Healthcare Providers and Fact Sheets for Recipients and Caregivers; mandatory reporting of adverse events to the FDA via MedWatch and the Vaccine Adverse Event Reporting System (VAERS); restrictions on who may prescribe, dispense, or administer the product; and requirements for specific storage, handling, or monitoring protocols. Pharmacists dispensing or administering EUA products are legally obligated to comply with all conditions specified in the authorization letter and fact sheets.
An EUA is inherently temporary and may be revoked by the FDA at any time if the criteria for issuance are no longer met — for instance, if new data demonstrate that the product's risks outweigh its benefits, or if an adequate approved alternative becomes available. An EUA also terminates automatically when the HHS Secretary's emergency declaration is terminated, unless the FDA explicitly extends or transitions the authorization. Following the end of the COVID-19 public health emergency, for example, several EUAs were allowed to expire while others were converted to full marketing authorizations.
Emergency Use Authorizations are not limited to a single product category. The FDA's EUA authority extends across the full spectrum of medical products — drugs, biologics, and devices — as well as to unapproved uses of already-approved products. Understanding the breadth of products that have received EUAs is important for pharmacists, who may encounter any of these categories in clinical practice and must be prepared to counsel patients, manage inventory, and comply with the specific conditions attached to each authorization.
| Product Category | Example Products | Key Pharmacist Responsibilities |
|---|---|---|
| Oral Antiviral Therapeutics | Nirmatrelvir/ritonavir (Paxlovid), molnupiravir (Lagevrio) | Screen for drug interactions (CYP3A4 substrates with Paxlovid), verify eligibility criteria (e.g., high-risk for severe COVID-19), provide Fact Sheet, report AEs via MedWatch |
| mRNA Vaccines | Pfizer-BioNTech COVID-19 Vaccine (Comirnaty EUA for updated formulations), Moderna COVID-19 Vaccine (Spikevax EUA for updated formulations) | Proper cold chain management (−25°C to −15°C for Moderna; −90°C to −60°C for original Pfizer), 15–30 minute observation post-administration, provide Fact Sheet, report AEs via VAERS |
| Rapid Diagnostic Tests | BinaxNOW COVID-19 Ag Card, Flowflex COVID-19 Antigen Home Test | Counsel on proper specimen collection technique, explain limitations of sensitivity vs. PCR, refer for confirmatory testing when indicated |
| Monoclonal Antibodies | Bebtelovimab, tixagevimab/cilgavimab (Evusheld — revoked) | Verify patient meets eligibility criteria (immunocompromised status, viral variant susceptibility), ensure appropriate administration setting with anaphylaxis management capabilities |
The following scenario walks through the decision-making process a pharmacist must follow when dispensing an EUA product. This illustrative case involves nirmatrelvir/ritonavir (Paxlovid), which was authorized under an EUA for the treatment of mild-to-moderate COVID-19 in patients at high risk for progression to severe disease.
Comparing the EUA pathway to the traditional New Drug Application (NDA) or Biologics License Application (BLA) approval process illuminates both the strengths and the inherent trade-offs of emergency authorization. Neither pathway is inherently superior; rather, each is optimized for different circumstances. Understanding these distinctions is essential for pharmacists who must communicate with patients about the regulatory status of the products they receive.
| Feature | EUA (Section 564) | Full Approval (NDA/BLA) |
|---|---|---|
| Evidentiary Standard | "May be effective" — totality of scientific evidence (may include preclinical, observational, or limited clinical data) | "Substantial evidence" — typically two adequate and well-controlled clinical trials demonstrating efficacy |
| Timeline | Days to weeks (dependent on data availability and urgency) | Months to years (standard review ~10 months; priority review ~6 months) |
| Duration | Temporary — linked to the duration of the declared emergency; may be revoked at any time | Permanent (unless withdrawn for safety or efficacy reasons) |
| Labeling | Fact Sheets for HCPs and patients (not full prescribing information) | Full prescribing information (package insert) including boxed warnings, contraindications, clinical pharmacology |
| Informed Consent | Patients must be informed of EUA status and their right to refuse; written consent not always required but Fact Sheet distribution is mandatory | Standard informed consent practices; no special notification requirements regarding regulatory status |
| Pharmacovigilance | Mandatory adverse event reporting as a condition of authorization (VAERS for vaccines, MedWatch for drugs/devices) | Post-marketing surveillance (MedWatch, FAERS); REMS may be required |
| Legal Liability | PREP Act and CARES Act provisions provide liability protections for manufacturers, distributors, and administrators of covered countermeasures during declared emergencies | Standard product liability framework applies; manufacturers may be sued for defective products |
The EUA framework does not exist in isolation. It intersects with several other expedited regulatory pathways that pharmacy students and practitioners should be able to distinguish. The FDA has developed a toolkit of accelerated pathways for products addressing serious or life-threatening conditions, and understanding where EUAs fit within this broader landscape is essential for NAPLEX preparation and for clinical decision-making regarding product availability and regulatory status.
| Pathway | Key Characteristics | Relationship to EUA |
|---|---|---|
| EUA (Section 564) | Temporary authorization during declared emergencies; "may be effective" standard; automatically terminates when emergency ends | — |
| Accelerated Approval | Full approval based on surrogate endpoints; requires confirmatory post-marketing trials; permanent unless withdrawn | A product may transition from EUA to accelerated approval if surrogate endpoint data are available; full approval requires verification of clinical benefit |
| Priority Review | FDA review within 6 months (vs. standard 10 months); requires significant improvement over existing therapy; full approval | Products under EUA may simultaneously have priority review applications pending; EUA is interim while the priority NDA/BLA is processed |
| Breakthrough Therapy | Designation enabling intensive FDA guidance and rolling review; preliminary clinical evidence of substantial improvement; leads to full approval | Several COVID-19 products held breakthrough therapy designation while also being authorized under EUA, enabling parallel development tracks |
| Fast Track | Designation for serious conditions with unmet need; enables rolling review and eligibility for accelerated approval; full approval | Fast Track and EUA address different stages — Fast Track accelerates the development/review process, while EUA provides interim market access before review is complete |
| Expanded Access (Compassionate Use) | Patient-level or intermediate access to investigational products for serious conditions; requires IND application; not a market authorization | EUA provides broader population-level access; expanded access is typically used for individual patients or small groups when an EUA has not been issued |
Looking forward, the experience of the COVID-19 pandemic has prompted significant discussion about refining the EUA framework. Key areas of active policy development include enhancing the transparency of EUA data submissions, establishing clearer criteria for EUA revocation when variant-specific resistance renders a product ineffective (as occurred with certain monoclonal antibodies), and defining more structured pathways for transitioning from EUA to full approval. The PREVENT Pandemics Act (2022) and related legislative proposals aim to codify lessons learned, including requirements for the FDA to publish data summaries supporting EUA decisions and to provide regular public updates on safety data accruing during the authorization period. These evolving standards will directly affect pharmacy practice as future emergencies — whether pandemic, bioterrorism, or radiological events — will inevitably trigger new EUAs.
An Emergency Use Authorization (EUA) is a temporary regulatory mechanism under Section 564 of the FD&C Act that permits the FDA to authorize unapproved medical products — including drugs, biologics, vaccines, and diagnostic devices — during a declared public health emergency. The EUA pathway requires a lower evidentiary threshold ("may be effective") than traditional approval ("substantial evidence"), and the FDA must determine that the known and potential benefits outweigh the known and potential risks and that no adequate approved alternative exists. EUAs are inherently temporary and may be revised or revoked as new evidence emerges or when the emergency declaration terminates.
Pharmacists play a critical frontline role in the EUA framework. They must verify patient eligibility per conditions of authorization, screen for drug interactions (particularly relevant for CYP3A4 interactions with ritonavir-containing products), provide mandatory Fact Sheets to patients, communicate the patient's right to refuse the EUA product, report adverse events through VAERS or MedWatch, and stay vigilant for FDA updates that may modify authorized uses. Understanding the EUA framework in the context of other expedited pathways — Accelerated Approval, Priority Review, Breakthrough Therapy, Fast Track, and Expanded Access — enables pharmacists to accurately counsel patients and make informed dispensing decisions during public health emergencies.